Rilpivirine-13C6

Rilpivirine-13C6 (R278474-13C6) is 13C labeled Rilpivirine. Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI) . Rilpivirine has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM) . Rilpivirine has a high genetic barrier to resistance development of HIV[1][2].

Product Specifications

Product Name Alternative

R278474-13C6; TMC278-13C6; DB08864-13C6

UNSPSC

12352005

Target

HIV; Isotope-Labeled Compounds; Reverse Transcriptase

Related Pathways

Anti-infection; Others

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

CC1=CC(/C=C/C#N)=CC(C)=C1NC2=CC=NC(N[13C]3=[13CH][13CH]=[13C]([13CH]=[13CH]3)C#N)=N2

Molecular Formula

C16 13C6H18N6

Molecular Weight

372.37

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Janssen PAJ, et, al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[ (1E) -2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) . J Med Chem. 2005 Mar 24;48 (6) :1901-9.|[3]Azijn H, et, al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010 Feb;54 (2) :718-27.